293 related articles for article (PubMed ID: 31874858)
61. Tumor Immune Microenvironment Characterization Identifies Prognosis and Immunotherapy-Related Gene Signatures in Melanoma.
Liu D; Yang X; Wu X
Front Immunol; 2021; 12():663495. PubMed ID: 34025664
[TBL] [Abstract][Full Text] [Related]
62. Granzyme family acts as a predict biomarker in cutaneous melanoma and indicates more benefit from anti-PD-1 immunotherapy.
Wu X; Wang X; Zhao Y; Li K; Yu B; Zhang J
Int J Med Sci; 2021; 18(7):1657-1669. PubMed ID: 33746582
[TBL] [Abstract][Full Text] [Related]
63. Stromal microenvironment promoted infiltration in esophageal adenocarcinoma and squamous cell carcinoma: a multi-cohort gene-based analysis.
Li J; Zeng Z; Jiang X; Zhang N; Gao Y; Luo Y; Sun W; Li S; Ren J; Gong Y; Xie C
Sci Rep; 2020 Oct; 10(1):18589. PubMed ID: 33122682
[TBL] [Abstract][Full Text] [Related]
64. A four-gene signature predicts survival and anti-CTLA4 immunotherapeutic responses based on immune classification of melanoma.
Mei Y; Chen MM; Liang H; Ma L
Commun Biol; 2021 Mar; 4(1):383. PubMed ID: 33753855
[TBL] [Abstract][Full Text] [Related]
65. PMEL as a Prognostic Biomarker and Negatively Associated With Immune Infiltration in Skin Cutaneous Melanoma (SKCM).
Zhang S; Chen K; Liu H; Jing C; Zhang X; Qu C; Yu S
J Immunother; 2021 Jul-Aug 01; 44(6):214-223. PubMed ID: 34028390
[TBL] [Abstract][Full Text] [Related]
66. C reactive protein impairs adaptive immunity in immune cells of patients with melanoma.
Yoshida T; Ichikawa J; Giuroiu I; Laino AS; Hao Y; Krogsgaard M; Vassallo M; Woods DM; Stephen Hodi F; Weber J
J Immunother Cancer; 2020 Apr; 8(1):. PubMed ID: 32303612
[TBL] [Abstract][Full Text] [Related]
67. Risk stratification of cutaneous melanoma reveals carcinogen metabolism enrichment and immune inhibition in high-risk patients.
Li X; Cai Y
Aging (Albany NY); 2020 Aug; 12(16):16457-16475. PubMed ID: 32858528
[TBL] [Abstract][Full Text] [Related]
68. The Immunology of Melanoma.
Ko JS
Clin Lab Med; 2017 Sep; 37(3):449-471. PubMed ID: 28802495
[TBL] [Abstract][Full Text] [Related]
69. Checkpoint blockade immunotherapy enhances the frequency and effector function of murine tumor-infiltrating T cells but does not alter TCRβ diversity.
Kuehm LM; Wolf K; Zahour J; DiPaolo RJ; Teague RM
Cancer Immunol Immunother; 2019 Jul; 68(7):1095-1106. PubMed ID: 31104075
[TBL] [Abstract][Full Text] [Related]
70. Pivotal factors associated with the immunosuppressive tumor microenvironment and melanoma metastasis.
Zhang C; Dang D; Cong L; Sun H; Cong X
Cancer Med; 2021 Jul; 10(14):4710-4720. PubMed ID: 34159752
[TBL] [Abstract][Full Text] [Related]
71. Single-cell RNA sequencing of lung adenocarcinoma reveals heterogeneity of immune response-related genes.
Ma KY; Schonnesen AA; Brock A; Van Den Berg C; Eckhardt SG; Liu Z; Jiang N
JCI Insight; 2019 Feb; 4(4):. PubMed ID: 30821712
[TBL] [Abstract][Full Text] [Related]
72. The Identification and Validation of a Robust Immune-Associated Gene Signature in Cutaneous Melanoma.
Song LB; Luan JC; Zhang QJ; Chen L; Wang HY; Cao XC; Song NH; Lu Y
J Immunol Res; 2021; 2021():6686284. PubMed ID: 33688507
[TBL] [Abstract][Full Text] [Related]
73. EZH2 Cooperates with DNA Methylation to Downregulate Key Tumor Suppressors and IFN Gene Signatures in Melanoma.
Tiffen J; Gallagher SJ; Filipp F; Gunatilake D; Emran AA; Cullinane C; Dutton-Register K; Aoude L; Hayward N; Chatterjee A; Rodger EJ; Eccles MR; Hersey P
J Invest Dermatol; 2020 Dec; 140(12):2442-2454.e5. PubMed ID: 32360600
[TBL] [Abstract][Full Text] [Related]
74. GPR182 limits antitumor immunity via chemokine scavenging in mouse melanoma models.
Torphy RJ; Sun Y; Lin R; Caffrey-Carr A; Fujiwara Y; Ho F; Miller EN; McCarter MD; Lyons TR; Schulick RD; Kedl RM; Zhu Y
Nat Commun; 2022 Jan; 13(1):97. PubMed ID: 35013216
[TBL] [Abstract][Full Text] [Related]
75. Mutant BRAF and MEK Inhibitors Regulate the Tumor Immune Microenvironment via Pyroptosis.
Erkes DA; Cai W; Sanchez IM; Purwin TJ; Rogers C; Field CO; Berger AC; Hartsough EJ; Rodeck U; Alnemri ES; Aplin AE
Cancer Discov; 2020 Feb; 10(2):254-269. PubMed ID: 31796433
[TBL] [Abstract][Full Text] [Related]
76. Molecular, clinicopathological, and immune correlates of LAG3 promoter DNA methylation in melanoma.
Fröhlich A; Sirokay J; Fietz S; Vogt TJ; Dietrich J; Zarbl R; Florin M; Kuster P; Saavedra G; Valladolid SR; Hoffmann F; Flatz L; Ring SS; Golletz C; Pietsch T; Strieth S; Brossart P; Gielen GH; Kristiansen G; Bootz F; Landsberg J; Dietrich D
EBioMedicine; 2020 Sep; 59():102962. PubMed ID: 32861198
[TBL] [Abstract][Full Text] [Related]
77. Closed system RT-qPCR as a potential companion diagnostic test for immunotherapy outcome in metastatic melanoma.
Gupta S; McCann L; Chan YGY; Lai EW; Wei W; Wong PF; Smithy JW; Weidler J; Rhees B; Bates M; Kluger HM; Rimm DL
J Immunother Cancer; 2019 Sep; 7(1):254. PubMed ID: 31533832
[TBL] [Abstract][Full Text] [Related]
78. Immune cells in the melanoma microenvironment hold information for prediction of the risk of recurrence and response to treatment.
Camisaschi C; Vallacchi V; Castelli C; Rivoltini L; Rodolfo M
Expert Rev Mol Diagn; 2014 Jul; 14(6):643-6. PubMed ID: 24914691
[TBL] [Abstract][Full Text] [Related]
79. Identification and Utilization of Biomarkers to Predict Response to Immune Checkpoint Inhibitors.
Gjoerup O; Brown CA; Ross JS; Huang RSP; Schrock A; Creeden J; Fabrizio D; Tolba K
AAPS J; 2020 Oct; 22(6):132. PubMed ID: 33057937
[TBL] [Abstract][Full Text] [Related]
80. T cells isolated from patients with checkpoint inhibitor-resistant melanoma are functional and can mediate tumor regression.
Andersen R; Borch TH; Draghi A; Gokuldass A; Rana MAH; Pedersen M; Nielsen M; Kongsted P; Kjeldsen JW; Westergaard MCW; Radic HD; Chamberlain CA; Hölmich LR; Hendel HW; Larsen MS; Met Ö; Svane IM; Donia M
Ann Oncol; 2018 Jul; 29(7):1575-1581. PubMed ID: 29688262
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
